Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2020

View Archived Issues

Data published from phase IIa COMBAT trial of BL-8040 plus pembrolizumab and chemotherapy

Healthspan, lifespan affected differently by caloric restriction

Rottapharm Biotech and Takis to co-develop novel DNA-based vaccine against COVID-19

IGM-8444 preclinical data support its clinical development as cancer immunotherapeutic

Stroke protection effects like night and day

Study suggests strategies to overcome cancer drug resistance

Primary endpoint met in phase II study of garadacimab as preventive treatment in HAE

IDE-397 selected as development candidate in IDEAYA's MAT2A synthetic lethality program

FDA accepts IND application for TAS-0953/HM-06

Novel DYNC2H1 gene variants linked to inherited retinal diseases

Preliminary phase I/IIa results for SNK-01 plus pembrolizumab in NSCLC

Momelotinib shows efficacy in RA and RA-induced anemia in preclinical rodent models

First-in-human data presented for BVAC-B in HER2-positive advanced gastric cancer

Teneobio develops novel bispecific T-cell redirecting antibody targeting CD3 and FRalpha

Jiangsu Chia Tai Tianqing Pharmaceutical divulges HBV antivirals

Inflazome patents NLRP3 inhibitors

Nanjing Sanhome Pharmaceutical synthesizes new TGFR-1 inhibitors

Shanghai De Novo Pharmatech identifies ATR kinase inhibitors

Positive topline data presented from two phase I studies of VE-202

Beijing Scitech-Mq Pharmaceuticals patents new compounds for cancer

Pigv341E mice mimic glycosylphosphatidylinositol biosynthesis deficiency

Soleno reports topline phase III results for DCCR as treatment of Prader-Willi syndrome

Phase I study of adoptive NK cell therapy in patients with relapsed/refractory AML

Assembly Biosciences initiates enrollment in phase I study of ABI-H3733

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...